Q-omics provides the consensus-scored C16orf82 profile across patient tissues and cancer cell-line models. C16orf82 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, C16orf82 is differentially expressed in 2, with the highest sampling consensus in BRCA. Additionally, C16orf82 RNA expression shows 6,646 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KICH, BRCA, and STAD as cancer lineages where C16orf82 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C16orf82 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C16orf82 survival associations across molecular data types. C16orf82 RNA expression shows survival associations in the most cancer types (14), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C16orf82 RNA expression–survival associations across cancer types. High C16orf82 expression shows unfavorable associations in KICH, KIRC, ACC, UCEC, BRCA and LIHC. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for C16orf82 RNA expression.
This table summarizes C16orf82 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for C16orf82. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C16orf82 shows lower tumor expression in BRCA and higher tumor expression in BLCA. The BRCA box plot shows higher C16orf82 RNA expression in normal versus tumor tissue (log2 FC = −0.036, t-test p < 0.001).
This table shows molecular features associated with C16orf82 in patient tissues and cancer cell lines. In patient samples, C16orf82 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, C16orf82 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and LUNG_NSCLC_LUAD.
